Closed · PAR-18-543 · CFDA 93.853 · Discretionary

CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
May 7, 2021
Close date
-
Expected awards

The verdict

CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

Varies
award range
Closed
application status
93.853
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

CREATE Bio Development Track: Preclinical and… is closed (last close May 7, 2021). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed May 7, 2021

Posted Dec 20 Closes May 7

Instrument

Cooperative Agreement

Description

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).

Small-business / for-profit corridor · PAR-18-543

CREATE Bio Development Track: Preclinical and… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

CREATE Bio Development Track: Preclinical and… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.853 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants